简介:AbstractHereditary spastic paraplegia type 56 (SPG56-HSP) is a rare autosomal recessive disorder caused by loss of function mutations in CYP2U1, leading to an early-onset limbs spasticity, often complicated by additional neurological or extra-neurological manifestations. Given its low prevalence, the molecular bases underlying SPG56-HSP are still poorly understood, and effective treatment options are still lacking. Recently, through the generation and characterization of the SPG56-HSP mouse model, we were able to take few important steps forward in expanding our knowledge of the molecular background underlying this complex disease. Leveraging the Cyp2u1-/- mouse model we were able to identify several new diagnostics biomarkers (vitamin B2, coenzyme Q, neopterin, and interferon-alpha), as well as to highlight the key role played by the folate pathway in SPG56-HSP pathogenesis, providing a potential treatment option. In this review, we discuss the major role played by the Cyp2u1-/- model in dissecting clinical and biological aspects of the disease, opening the way to a series of new research paths ranging from clinical trials, biomarker testing, and to the expansion of the underlying genetic and molecular, emphasizing how basic mouse model characterization could contribute to advance research in the context of rare disorders.
简介:摘要目的探讨游泳池肉芽肿的临床病理特征。方法回顾性分析2018年1月至2021年1月天津市中医药研究院附属医院56例游泳池肉芽肿的临床及病理特点。结果56例患者中,男16例,女40例,平均年龄60.84岁。水产从业人员及居民日常烹饪中处理受感染的鱼或海产品是本组病例感染的主要暴露方式(31/56),平均潜伏期4.58周,平均诊断时间为3.19个月;56例患者皮损均位于上肢,以红斑、丘疹结节为主,有时表现为脓疱、溃疡、肉芽肿或疣状斑块。单发孤立性皮损11例,36例表现为孢子丝菌病串珠样皮损,6例表现为双侧串珠样皮损。组织病理学上除4例无特异性改变外,52例患者表现为感染性肉芽肿,其中37例出现特征性的渗出坏死,中央为不等量的纤维素样渗出或坏死物,其内或周边伴随大量中性粒细胞、组织细胞及多核巨细胞浸润。56例病原微生物宏基因组DNA测序均检测到海分枝杆菌序列。结论天津地区游泳池肉芽肿以老年女性患病为主,处理受感染的鱼或海产品是最主要的暴露方式,组织病理可表现为特征性的渗出坏死性肉芽肿。
简介:摘要目的对小儿疱疹性咽峡炎患者给予康复新治疗的效果分析与评价。方法选取我院2017年6月至2018年4月期间收治的56例疱疹性咽峡炎患儿为研究对象,根据患儿入院就诊编号随机分为观察组与对照组各28例,两组患儿均给予常规支持治疗,对照组患儿给予对症治疗,包括利巴韦林、蒲地蓝消炎口服液、布洛芬混悬液口服给药,观察组在对照组基础上给予康复新给药治疗,对两组患儿发热、食欲减退、疱疹等临床症状改善时间及治疗效果进行评定比较。结果观察组患儿治疗总有效率显著高于对照组(P<0.05);观察组患儿发热、食欲减退、疱疹等临床症状体征的改善时间均显著短于对照组(P<0.05)。结论对疱疹性咽峡炎患儿在常规对症与支持治疗的基础上,给予康复新给药,能够显著提高临床疗效,缩短临床症状改善时间。